(Q43879015)

27 November 2017

title

Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers (English)

1 reference

27 November 2017

Antoon H van Lierop

1

1 reference

27 November 2017

Neveen A T Hamdy

2

1 reference

27 November 2017

Martje E van Egmond

3

1 reference

27 November 2017

Egbert Bakker

4

1 reference

27 November 2017

Freek G Dikkers

5

1 reference

27 November 2017

Socrates E Papapoulos

6

1 reference

27 November 2017

publication date

1 April 2013

1 reference

Journal of Bone and Mineral Research

27 November 2017

published in

1 reference

27 November 2017

volume

28

1 reference

27 November 2017

issue

4

1 reference

27 November 2017

page(s)

848-854

1 reference

The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

The natural history of sclerosteosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Glucocorticoids are not always deleterious for bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

A rare cause of facial nerve palsy in children: hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Two cases of Van Buchem's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Van Buchem disease: lifetime evolution of radioclinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Bone mineral density in sclerosteosis; affected individuals and gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

Sclerostin in Mineralized Matrices and van Buchem Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1794

21 January 2018

Identifiers

DOI

10.1002/JBMR.1794

1 reference

27 November 2017

1 reference